NCT02260635

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

A Double-Blind Efficacy and Safety Study of Evacetrapib Followed by an Open-Label Extension in Japanese Patients With Primary Hypercholesterolemia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib in Japanese participants with primary hypercholesterolemia. The double blind treatment period will last for 12 weeks and the open-label extension period will last for an additional 40 weeks.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Evacetrapib	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2014-11-01
• Primary completion: 2015-07-01
• Completion: 2015-12-01
• First posted: 2014-10-09
• Last updated: 2018-10-09
• Results posted: 2018-10-09

Locations

2 sites across 1 country: Japan